These are the recommendations of French glaucoma and retina experts on the management of ocular hypertension (OHT) observed in 1/3 of cases after intravitreal steroid implant injections. They are an update to the recommendations first published in 2017. There are two implants on the French market: the dexamethasone (DEXi) and fluocinolone acetonide (FAci) implants. It is important to know the pressure status before injecting a patient with a steroid implant. Monitoring of the IOP adapted to the specific drug is necessary throughout follow-up and reinjections. Real-life studies have made it possible to optimize the management algorithm by significantly increasing the safety of use of these implants. A corticosteroid test with DEXi is necessary before switching to FAci to optimize the pressure tolerance of the latter. In addition to topical glaucoma medications, SLT laser can be considered in the therapeutic arsenal for the management of steroid-induced OHT and future injections.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1016/j.jfo.2023.05.003 | DOI Listing |
J Clin Med
January 2025
Department of Ophthalmology, University of Bonn, 53127 Bonn, Germany.
: The PreserFlo™ MicroShunt (PFMS) is a bleb-forming device considered to be less invasive than traditional glaucoma surgery such as trabeculectomy. This study evaluates the 1-year success rates as well as safety profile of PFMS in patients having high intraocular pressure (IOP) and/or glaucoma refractory to drop therapy with a history of prior intravitreal dexamethasone therapy. : A total of 16 eyes after PFMS implantation due to elevated IOP after intravitreal dexamethasone implant (DEX-I) administration were included in this retrospective cohort study.
View Article and Find Full Text PDFInt J Mol Sci
January 2025
Electron Microscopy Center, Department of Biological Sciences, State University of Santa Cruz, Ilheus 45662-900, Brazil.
Hypothyroidism causes ovarian dysfunction and infertility in women and animals and impairs the hypothalamic expression of kisspeptin (Kp). However, kisspeptin is also expressed in the genital system, and the lack of the Kp receptor (Kiss1r) in the uterus is linked to reduced implantation rates. This study investigated the impact of hypothyroidism on the uterine expression of Kp and Kiss1r in female rats throughout the estrous cycle and the associated changes in uterine activity modulators.
View Article and Find Full Text PDFDiagnostics (Basel)
January 2025
Department of Ophthalmology, Policlinico Riuniti Foggia, University of Foggia, 71122 Foggia, Italy.
: In this study, we evaluated the incidence of cystoid macular edema (CME) after pars plana vitrectomy (PPV) for different retinal pathologies and assessed the role of optical coherence tomography (OCT) biomarkers in guiding treatment decisions in post-surgical CME patients who were refractory to medical therapy over a follow-up period of 12 months. : Medical records of consecutive pseudophakic patients, who underwent PPV for different retinal pathologies, were retrospectively evaluated in this single-center, uncontrolled study. The incidence of post-PPV CME was assessed.
View Article and Find Full Text PDFNanoImpact
January 2025
Reproductive Medicine Center, Zhongnan Hospital, Wuhan University, Wuhan 430071, Hubei Province, PR China; Hubei Clinical Research Center for Prenatal Diagnosis and Birth Health, Wuhan 430071, Hubei Province, PR China; Wuhan Clinical Research Center for Reproductive Science and Birth Health, Wuhan 430071, Hubei Province, PR China. Electronic address:
Long-term effects of microplastics (MPs) exposure have been demonstrated to impair reproductive function. However, in real world, the exposure level of MP is not constant and it may vary in different individuals. This study aims to evaluate the impact of short-term exposure to MPs on ovarian and endometrial function in rat models.
View Article and Find Full Text PDFSci Rep
January 2025
Division of Hematology and Oncology, University of California, 1450 3rd Street, San Francisco, CA, 94143, USA.
For individuals at high risk of developing breast cancer, interventions to mitigate this risk include surgical removal of their breasts and ovaries or five years treatment with the anti-estrogen tamoxifen or aromatase inhibitors. We hypothesized that a silicone based anti-estrogen-eluting implant placed within the breast would provide the risk reduction benefit of hormonal therapy, but without the adverse effects that limit compliance. To this end, we demonstrate that when placed adjacent to mammary tissue in the 7,12-dimethylbenz[a]anthracene-induced rat breast cancer model a fulvestrant-eluting implant delays breast cancer with minimal systemic exposure.
View Article and Find Full Text PDFEnter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!